30 June - 3 July 2021 Virtual Conference
![]() |
![]() |
![]() |
![]() |
SO-1 | The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey | Joanne Franklin | ![]() |
![]() |
|||
PD-1 | MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress) | Natalie Pizzimenti | ![]() |
![]() |
|||
P-1 | Health-related quality of life of rectal cancer survivors treated with curative intent | André Ferreira | ![]() |
![]() |
|||
P-2 | First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis | Sik Kwan Chan | ![]() |
![]() |
|||
PD-2 | Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer | Richard Kim | ![]() |
![]() |
|||
SO-3 | Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe | Julien Taieb | ![]() |
![]() |
|||
PD-3 | Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study | Roger von Moos | ![]() |
![]() |
|||
P-3 | Gastric cancer: 10-year survival | Oleg Kshivets | ![]() |
![]() |
|||
P-4 | Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer | sonia Ben Nasr | ![]() |
![]() |
|||
O-4 | Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium | Corinna Slawinski | ![]() |
![]() |
|||
SO-4 | Progression-free survival in patients With cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response | Ghassan Abou-Alfa | ![]() |
![]() |
|||
LBA-5 | Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer | Zev Wainberg | ![]() |
![]() |
|||
PD-5 | Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet bevacizumab | Riccardo Giampieri | ![]() |
![]() |
|||
SO-5 | Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma | Sarbajit Mukherjee | ![]() |
![]() |
|||
P-5 | The use of complementary and alternative medicine among colorectal cancer patients in Tunisia | sonia Ben Nasr | ![]() |
![]() |
|||
O-6 | Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial | Naoki Izawa | ![]() |
![]() |
|||
P-6 | Spatio-temporal distribution pattern of pancreatic cancer mortality rate in Peru between 2003-2017 | Claudio Flores | ![]() |
![]() |
|||
PD-6 | Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology | Yiguang Lin | ![]() |
![]() |
|||
SO-6 | Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial | Maximilian Kloft | ![]() |
![]() |
|||
O-7 | FOLFIRI napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study | Manish A. Shah | ![]() |
![]() |
|||
P-7 | How much can GIT cancer patients afford for effective and safe treatment? | Rasha Aboelhassan | ![]() |
![]() |
|||
SO-7 | The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database | Lei Deng | ![]() |
![]() |
|||
P-8 | Nutritional status among colorectal cancer patients in Tunisia | sonia Ben Nasr | ![]() |
![]() |
|||
P-9 | Prognostic role of preoperative inflammation parameters in predicting postoperative complications of colorectal cancer surgery. | sonia Ben Nasr | ![]() |
![]() |
|||
SO-9 | Analysis of the immune-related endpoints of the mismatch repairdeficient non-endometrial solid cancers cohort from the GARNET study | Thierry André | ![]() |
![]() |
|||
SO-10 | An open-label, multi-centre, phase Ib/II study of PI3K ive inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway | Minkyu Jung | ![]() |
![]() |
|||
P-10 | Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia | sonia Ben Nasr | ![]() |
![]() |
|||
P-11 | GAME score in patients with liver metastases from colorectal cancer | Wala Ben Kridis | ![]() |
![]() |
|||
O-11 | Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan | Hiromichi Shirasu | ![]() |
![]() |
|||
P-12 | Long intergenic non-protein coding RNA 1094 regulates the progression of gastric cancer | Ouyang Ge | ![]() |
![]() |
|||
O-12 | Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study | Lisa Salvatore | ![]() |
![]() |
|||
P-13 | Efficacy of FOLFOX4 regimen with advanced hepatocellular carcinoma and prognostic factors for survival | Chawalit Chayangsu | ![]() |
![]() |
|||
SO-13 | KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients | Emerik Osterlund | ![]() |
![]() |
|||
O-13 | Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) | Yu Sunakawa | ![]() |
![]() |
|||
P-14 | The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer | bengueddach aicha | ![]() |
![]() |
|||
O-14 | Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma | Kohei Shitara | ![]() |
![]() |
|||
SO-14 | The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study | Yuki Matsubara | ![]() |
![]() |
|||
SO-15 | Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study | Gabor Liposits | ![]() |
![]() |
|||
P-15 | Diagnostic potential of erythrocyte and serum fatty acids in spotting adenomatous polyps and identifying the early stages of colorectal cancer depending on tumor localization | Margarita Kruchinina | ![]() |
![]() |
|||
P-16 | How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia | Mirjana Pavlovic | ![]() |
![]() |
|||
SO-16 | Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595) | Pia Osterlund | ![]() |
![]() |
|||
P-17 | CT colonography: A minimally invasive screening option for colorectal cancer | Jagmeet Grewal | ![]() |
![]() |
|||
SO-18 | Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study | Julien Taieb | ![]() |
![]() |
|||
P-18 | Phase Ib study of niraparib plus tebotelimab in patients with advanced or metastatic gastric cancer after prior treatment failure | Bo Lyu | ![]() |
![]() |
|||
SO-19 | A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial | Naoki Izawa | ![]() |
![]() |
|||
P-19 | Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial | Stephen Lam Chan | ![]() |
![]() |
|||
SO-20 | Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study. | Carlotta Antoniotti | ![]() |
![]() |
|||
P-20 | Concurrent chemo-radiotherapy in anal squamous cell carcinomas: A 10-year retrospective review of a tertiary centre experience | Abdelfattah Elmasry | ![]() |
![]() |
|||
SO-21 | Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database | Firas Baidoun | ![]() |
![]() |
|||
P-21 | Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States | Daniel Beachler | ![]() |
![]() |
|||
P-22 | Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial | Igor Monsellato | ![]() |
![]() |
|||
SO-23 | The genomic temporal heterogeneity of circulating tumor DNA in metastatic colorectal cancer under first-line treatment | Feng Wang | ![]() |
![]() |
|||
P-23 | Experience of concurrent chemoradiotherapy for pancreatic cancer in a large university hospital | Gemma Searle | ![]() |
![]() |
|||
P-24 | A prospective phase 1b dose de-escalation open-label clinical study to evaluate the safety and efficacy of sorafenib with metformin and atorvastatin in advanced hepatocellular carcinoma (SMASH) | PRABHAT BHARGAVA | ![]() |
![]() |
|||
SO-24 | Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study | Paolo Manca | ![]() |
![]() |
|||
SO-25 | Global rise in early-onset colorectal cancer: An association with antibiotic consumption? | Sarah Perrott | ![]() |
![]() |
|||
P-25 | A review of circulating exosomal biomarkers in the diagnosis of pancreatic cancer | Menazir Sha | ![]() |
![]() |
|||
SO-26 | In-silico Lynch syndrome-related neoantigens prediction for a dendritic cell-based cancer prevention vaccine | Cristina Bayó | ![]() |
![]() |
|||
P-27 | The efficacy and safety of XELOX/SOX plus bevacizumab as neoadjuvant chemotherapy for locally advanced rectal cancer compared with XELOX/SOX: A retrospective study | Nanako Sakaguchi | ![]() |
![]() |
|||
SO-28 | Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib cetuximab /- binimetinib in BEACON CRC | Michele Springer | ![]() |
![]() |
|||
P-28 | Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study | yui okada | ![]() |
![]() |
|||
SO-29 | Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: an expanded dataset | Valentina Boni | ![]() |
![]() |
|||
P-29 | Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience | Karolina K&281;dzierska-Kapuza | ![]() |
![]() |
|||
SO-30 | Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study | Ali Shamseddine | ![]() |
![]() |
|||
SO-31 | ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer | Hyun Cheol Chung | ![]() |
![]() |
|||
P-31 | Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies | Nieves Martinez Lago | ![]() |
![]() |
|||
P-32 | SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome | Budhi Ida Bagus | ![]() |
![]() |
|||
P-33 | Results of initial DPYD screening for cancer patients receiving fluoropyrimidines | Matilde Bolaños | ![]() |
![]() |
|||
P-34 | Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors | Nieves Martinez Lago | ![]() |
![]() |
|||
P-35 | HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment. | Ken Ito | ![]() |
![]() |
|||
P-37 | SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress) | Tanios Bekaii-Saab | ![]() |
![]() |
|||
P-38 | Unmet needs and concerns of Russian patients with CRC: Analysis of Russian internet postings | Aleksandr Krotkevich | ![]() |
![]() |
|||
P-39 | The role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib | Margherita Rimini | ![]() |
![]() |
|||
P-40 | Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study | Margherita Rimini | ![]() |
![]() |
|||
P-42 | Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study | Gerardo Rosati | ![]() |
![]() |
|||
P-43 | C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in mestizo patients with metastatic colorectal cancer. | Allan Ramos-Esquivel | ![]() |
![]() |
|||
P-44 | Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma | Wanpeng Wang | ![]() |
![]() |
|||
P-45 | An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer | Kanwal Raghav | ![]() |
![]() |
|||
P-46 | Integrated transcriptomics and the exploration of cancer-promoting genes CDKN3 in esophageal squamous cell cancer | Yan Pan | ![]() |
![]() |
|||
P-47 | 5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors | RENATA PEIXOTO | ![]() |
![]() |
|||
P-48 | Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients | Varun Goel | ![]() |
![]() |
|||
P-49 | Oesophageal neuroendocrine carcinoma: retrospective evaluation of outcomes from a UK tertiary centre | Michael Tilby | ![]() |
![]() |
|||
P-50 | Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study | Esther Álvarez-García | ![]() |
![]() |
|||
P-51 | Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients | Erika Martinelli | ![]() |
![]() |
|||
P-52 | Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location | Stefan Kasper | ![]() |
![]() |
|||
P-53 | Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis | Rachel Broadbent | ![]() |
![]() |
|||
P-54 | Higher muscle mass is associated with better response to concurrent neoadjuvant chemoradiotherapy in rectal cancer patients | Kiril Zhelev | ![]() |
![]() |
|||
P-55 | Constructing a Hybrid Control for the MORPHEUS Colorectal Cancer (CRC) Trial Using IMblaze370 Historical Trial Data | Neil Segal | ![]() |
![]() |
|||
P-56 | A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR) | Hiroyuki Takeda | ![]() |
![]() |
|||
P-57 | US real-world ramucirumab and immune checkpoint inhibitor (ICI) treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer. | Julie Beyrer | ![]() |
![]() |
|||
P-58 | Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria BERING CRC | Frank Reichenbach | ![]() |
![]() |
|||
P-60 | Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy | Juan Luis Sanz | ![]() |
![]() |
|||
P-61 | Relatlimab nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 | Kathryn Woods | ![]() |
![]() |
|||
P-62 | Overall survival of patients with pancreatic cancer | Claudio Flores | ![]() |
![]() |
|||
P-63 | MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - randomised, double-blind, placebo-controlled, Phase 3 study | Yelena Yuriy Janjigian | ![]() |
![]() |
|||
P-64 | The?impact of?sarcopenia?on overall survival?among?cholangiocarcinoma patients: A systematic review?and meta-analysis | Jeannette Tandiono | ![]() |
![]() |
|||
P-65 | Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review | Jeannette Tandiono | ![]() |
![]() |
|||
P-66 | Experience in our center of bone events not related to the disease in patients with locally advanced or metastatic adenocarcinoma of the pancreas | INMACULADA GALLEGO JIMENEZ | ![]() |
![]() |
|||
P-67 | Prognostic implication of HER2 overexpression in surgically treated patients with gastric cancer | Erkhembayar Enkhbat | ![]() |
![]() |
|||
P-68 | Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting | Clara Garcia Grove | ![]() |
![]() |
|||
P-69 | Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience. | Alessandro Rizzo | ![]() |
![]() |
|||
P-70 | First-in-human study of highly ive FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors | Cori Ann Sherwin | ![]() |
![]() |
|||
P-71 | KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation | Josep Tabernero | ![]() |
![]() |
|||
P-72 | A Patient Preference Study on Risk Thresholds to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma | Neehar Parikh | ![]() |
![]() |
|||
P-73 | The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study | Floriana Camarda | ![]() |
![]() |
|||
P-74 | The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study | Maria Grazia Maratta | ![]() |
![]() |
|||
P-75 | Impact of an educational activity on the knowledge of oncologists regarding the latest clinical trial data on HER2-directed therapies for gastric and colorectal cancer | Nabil Dorkhom | ![]() |
![]() |
|||
P-76 | Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC | Nabil Dorkhom | ![]() |
![]() |
|||
P-78 | Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib | Jasmine Huynh | ![]() |
![]() |
|||
P-79 | HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody | Ken Ito | ![]() |
![]() |
|||
P-80 | Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON | Open Health Open Health | ![]() |
![]() |
|||
P-81 | HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment | Ken Ito | ![]() |
![]() |
|||
P-82 | Impact of type 2 diabetes mellitus in overall survival and clinical features of Latin patients with colorectal cancer: A 15-year follow-up | German Calderillo | ![]() |
![]() |
|||
P-83 | The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1 | Koshi Kumagai | ![]() |
![]() |
|||
P-84 | Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer | Jose Angel García-Cuesta | ![]() |
![]() |
|||
P-85 | Relationship between microsatellite instability and neoadjuvant chemotherapy response in gastric or gastroesophageal junction cancer: A meta-analysis | Selin Akturk Esen | ![]() |
![]() |
|||
P-86 | The importance of sphingosine kinase 1 isoform expression in the gut-liver axis | Hongjie Chen | ![]() |
![]() |
|||
P-87 | Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study | Mariana Sardinha | ![]() |
![]() |
|||
P-89 | The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma | Feng Bi | ![]() |
![]() |
|||
P-90 | Combined high expression of MAP17 and fascin-1 in colorectal cancer: Targeted therapy in need? | Athanasios Tampakis | ![]() |
![]() |
|||
P-91 | Safety and efficacy of perioperative FLOT in elderly patients: Real-world data | Mafalda Baleiras | ![]() |
![]() |
|||
P-92 | The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists | Simone Leyden | ![]() |
![]() |
|||
P-93 | The characteristics and prognosis of extragastrointestinal stromal tumors: A single center retrospective analysis of 31 patients | Mingchun Mu | ![]() |
![]() |
|||
P-94 | Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol | Joana Mendona | ![]() |
![]() |
|||
P-95 | EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers | Kei Muro | ![]() |
![]() |
|||
P-96 | Analysis of three biographical times of disease in the IMbrave 150 study: A new measure to assess clinical effect | Eduardo Ceballos Barbancho | ![]() |
![]() |
|||
P-97 | Updated results of HGCSG1603: a phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer | Michio Nakamura | ![]() |
![]() |
|||
P-98 | A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma | Aimin Zhang | ![]() |
![]() |
|||
P-99 | Circulating RNA detection, circulating tumor cells count (CTC) and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials | Susana Rodríguez | ![]() |
![]() |
|||
P-100 | A phase II study of first-line chemotherapy initiating FOLFIRIcetuximab and switching to FOLFIRIbevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial | Hirokazu Shoji | ![]() |
![]() |
|||
P-101 | Survival of early-onset gastric signet ring cell carcinoma in the Korean population between 2010 and 2015: Analysis of the Korean central cancer registry database | Hee Man Kim | ![]() |
![]() |
|||
P-102 | The importance of maintenance chemotherapy in the first and second lines of treatment of metastatic colorectal cancer | Danila Gridnev | ![]() |
![]() |
|||
P-103 | Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors | Erin McGillivray | ![]() |
![]() |
|||
P-104 | Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy | Stefan de Vogel | ![]() |
![]() |
|||
P-105 | POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer | Hedy Kindler | ![]() |
![]() |
|||
P-106 | Descriptive study of long-term survivors with advanced pancreatic cancer | Victoria Aviño Tarazona | ![]() |
![]() |
|||
P-107 | Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib | Anisha Patel | ![]() |
![]() |
|||
P-108 | Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma | Maen Abdelrahim | ![]() |
![]() |
|||
P-109 | CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer a feasibility study | Somnath Mukherjee | ![]() |
![]() |
|||
P-110 | Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy? | Shiho Murata | ![]() |
![]() |
|||
P-111 | PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification | Syneos Health | ![]() |
![]() |
|||
P-112 | Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: the VHIO experience | stefania napoli | ![]() |
![]() |
|||
P-113 | FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement | Ulita Nonemaker | ![]() |
![]() |
|||
P-114 | Claudin 18 isoform expression in gastric adenocarcinoma and pancreatic adenocarcinoma | Takeshi Saito | ![]() |
![]() |
|||
P-116 | What have we learned about of trifluridine/tipiracil (TAS-102)? Real World Data at four GEODA hospitals (Spain) | JULIA MARTÍNEZ PÉREZ | ![]() |
![]() |
|||
P-117 | Survival Outcomes following Systemic Chemotherapy in Stage IVA/B High-grade Mucinous Appendiceal Cancer after Unsuccessful Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Ekaterina Baron | ![]() |
![]() |
|||
P-118 | Survival Outcomes of Adjuvant Chemotherapy in Stage IVA/B High-grade Appendiceal Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Ekaterina Baron | ![]() |
![]() |
|||
P-119 | Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer | Vanessa Wookey | ![]() |
![]() |
|||
P-120 | Pre-assessment tool predicting complication following oesophagogastric resection: Sarcopenia or incremental shuttle walk test | Yashashwi Sinha | ![]() |
![]() |
|||
P-121 | Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study | Mikhail Fedyannin | ![]() |
![]() |
|||
P-122 | Gastrointestinal side effects of morphine in cancer pain: A comparison between the smoking and non-smoking patients | Fatima Zahra Hijri | ![]() |
![]() |
|||
P-123 | Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil | Victoria Aviño Tarazona | ![]() |
![]() |
|||
P-124 | Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma | Yung-Yeh Su | ![]() |
![]() |
|||
P-125 | Caring for more than survival: A survey of patient preferences in advanced hepatocellular carcinoma | Siu Hing Lo | ![]() |
![]() |
|||
P-126 | Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load | Chiun Hsu | ![]() |
![]() |
|||
P-127 | Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy | Andrea Pretta | ![]() |
![]() |
|||
P-128 | Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus | Andrea Pretta | ![]() |
![]() |
|||
P-129 | Concomitant RAS and BRAF mutations: impact on overall survival and progression free survival in metastatic colorectal cancer patients | Andrea Pretta | ![]() |
![]() |
|||
P-130 | Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study | Niklaus Schaefer | ![]() |
![]() |
|||
P-131 | External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy | Riccardo Giampieri | ![]() |
![]() |
|||
P-132 | Molecular profiling of KIT and PDGFRA in Chilean GIST patients: A Latin-American perspective | Matias Muñoz-Medel | ![]() |
![]() |
|||
P-133 | The watch-and-wait approach in stage IV rectal cancer patients: A good alternative for TME surgery? | Petra Custers | ![]() |
![]() |
|||
P-134 | Social determinants of health are risk factors for early onset colorectal cancer in Appalachia | William Oelsner | ![]() |
![]() |
|||
P-135 | Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress | Daneng Li | ![]() |
![]() |
|||
P-136 | Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool | Carlos Galmarini | ![]() |
![]() |
|||
P-137 | Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer | Miriam Koopman | ![]() |
![]() |
|||
P-138 | Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer | Daniel Catenacci | ![]() |
![]() |
|||
P-139 | A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated ed solid tumors: Pancreatic cancer cohort | Hyun Cheol Chung | ![]() |
![]() |
|||
P-140 | A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers | Hi-Jen Tsai | ![]() |
![]() |
|||
P-141 | Neoadjuvant chemotherapy with docetaxel, nedaplatin, and 5-FU for resectable esophageal cancer: A single center retrospective study | Satoko Shindo | ![]() |
![]() |
|||
P-142 | Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study | Hongfei Zhang | ![]() |
![]() |
|||
P-143 | Polyphyllin ? and resiquimod-loaded injectable hydrogels promote the polarization of tumor-associated macrophages and enhance gastric cancer immunotherapy | Hanqing Qian | ![]() |
![]() |
|||
P-144 | A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2 metastatic gastric cancer | Ying Wu | ![]() |
![]() |
|||
P-145 | Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer | Toshihiko Matsumoto | ![]() |
![]() |
|||
P-146 | Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer | Toshihiko Matsumoto | ![]() |
![]() |
|||
P-147 | Epigenetic gene somatic mutations in gastric cancer | Alexey Kalinkin | ![]() |
![]() |
|||
P-148 | Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling | Cristina Morelli | ![]() |
![]() |
|||
P-149 | Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer | Massimiliano Salati | ![]() |
![]() |
|||
P-150 | Insights into the gastric and oesophageal cancer patient experience: Results of a pan-European patient survey | Zorana Maravic | ![]() |
![]() |
|||
P-151 | The prognostic value of TCF1CD8T cell in primary small cell carcinoma of the esophagus | Lin Ma | ![]() |
![]() |
|||
P-152 | Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil | Mateusz Malik | ![]() |
![]() |
|||
P-153 | Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center | Zara Vidales Sepulveda | ![]() |
![]() |
|||
P-154 | A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 | Josep Tabernero | ![]() |
![]() |
|||
P-155 | A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis | Kazuhiro Shiraishi | ![]() |
![]() |
|||
P-156 | A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer | Prianka Singh | ![]() |
![]() |
|||
P-157 | Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level | Benjamin Staum | ![]() |
![]() |
|||
P-158 | Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma | Giuseppina Arbore | ![]() |
![]() |
|||
P-159 | HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction | Rita Laeufle | ![]() |
![]() |
|||
P-160 | Young Latin American population with colorectal cancer: Characteristics of bad prognosis | German Calderillo | ![]() |
![]() |
|||
P-161 | The diagnostic methods for detection of Helicobacter pylori infection: A comparative approach to invasive methods. | Fabian Castro-Valencia | ![]() |
![]() |
|||
P-162 | Universally adopted Vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and corrleated with neutrophil/lymphocyte ratio | michela rofei | ![]() |
![]() |
|||
P-163 | Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma | Nadia Hitchen | ![]() |
![]() |
|||
P-164 | MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer | Maria Alsina | ![]() |
![]() |
|||
P-165 | Comparative study on the clinical effect of hand-assisted laparoscopic and laparoscopic gastrectomy for gastric stromal tumor | Qu-xia Zhang | ![]() |
![]() |
|||
P-166 | Operative versus nonoperative treatment for stage 0 rectal cancer following chemoradiation therapy | Fatima Aurora Aires | ![]() |
![]() |
|||
P-167 | Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients | Binyi Xiao | ![]() |
![]() |
|||
P-168 | Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study | Vilma Pacheco-Barcia | ![]() |
![]() |
|||
P-169 | Tumor-infiltrating lymphocytes in colorectal cancer: A clinical outcome predictor | Marina Vitorino | ![]() |
![]() |
|||
P-170 | Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center | Anas Chennouf | ![]() |
![]() |
|||
P-171 | Does metastasectomy really improve survival in gastric cancer? | Marcelle Cesca | ![]() |
![]() |
|||
P-172 | PTHrP and SPARC expressions in human colorectal cancer: An in silico analysis | Pedro Matías Carriere | ![]() |
![]() |
|||
P-173 | Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study | Myrto Kastrisiou | ![]() |
![]() |
|||
P-174 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2 gastric or gastroesophageal junction adenocarcinoma: Trial in progress | Natalie Pizzimenti | ![]() |
![]() |
|||
P-175 | Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors | Martín Igor Gómez-Randulfe Rodríguez | ![]() |
![]() |
|||
P-176 | A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04) | Vaibhav Sahai | ![]() |
![]() |
|||
P-177 | Early onset colorectal cancer outcomes in a public Uruguayan cancer centre | Santiago Fontes | ![]() |
![]() |
|||
P-178 | Rego-Nivo for the treatment of HCC refractory to chemotherapy after the 2nd line | yasmina ben merabet | ![]() |
![]() |
|||
P-180 | Rectal cancer in the elderly: Characteristics, management and outcomes from a single centre retrospective cohort review | Ruba A Hamed | ![]() |
![]() |
|||
P-181 | Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial) | SUWA YUSUKE | ![]() |
![]() |
|||
P-182 | A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer | Tatsuki Ikoma | ![]() |
![]() |
|||
P-183 | Laparoscopic colorectal resection for elderly patients aged 80 years or older: A propensity score analysis | Ryo Inada | ![]() |
![]() |
|||
P-184 | Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma | Adi Haber | ![]() |
![]() |
|||
P-185 | A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewerts type II-III adenocarcinoma of esophagogastric junction | Qun Zhao | ![]() |
![]() |
|||
P-186 | Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients | Sung Yong Han | ![]() |
![]() |
|||
P-187 | Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study | Qiao-xuan Wang | ![]() |
![]() |
|||
P-188 | Propensity score analysis of outcomes following laparoscopic or open radical resection for gallbladder carcinoma in T2 and T3 stages | changwei dou | ![]() |
![]() |
|||
P-189 | Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort | Ayano Sakai | ![]() |
![]() |
|||
P-190 | Exploring possible predictors of survival in hepatocellular carcinoma | Ins Eiriz | ![]() |
![]() |
|||
P-191 | Prognostic factors of colorectal cancer liver metastasectomy | Ins Costa | ![]() |
![]() |
|||
P-192 | Chemoradiation for anal canal carcinoma: A multicentric retrospective cohort study | Ines Leao | ![]() |
![]() |
|||
P-193 | Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study | Hiroki Hashida | ![]() |
![]() |
|||
P-194 | Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin | varun goel | ![]() |
![]() |
|||
P-195 | Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients | Jean Paul NSHIZIRUNGU | ![]() |
![]() |
|||
P-196 | Frequency, biological behaviour and survival nomograms discrimination in non-KIT mutated gastrointestinal stromal tumors | Tiago Alpoim | ![]() |
![]() |
|||
P-197 | The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO) | Marcelle Cesca | ![]() |
![]() |
|||
P-198 | Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy | CLAUDIA CARDONE | ![]() |
![]() |
|||
P-199 | Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy | Davide Ciardiello | ![]() |
![]() |
|||
P-200 | A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202 | Ken Nakata | ![]() |
![]() |
|||
P-201 | Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors | Marcelle Cesca | ![]() |
![]() |
|||
P-202 | Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer | Joana Marinho | ![]() |
![]() |
|||
P-203 | Relationship of myelotoxicity and of gastrointestinal toxicity with the treatment outcome in trials of second-line chemotherapy of patients with metastatic colorectal cancer | Antonella Venturino | ![]() |
![]() |
|||
P-204 | Survival improvement from the addition of biologics is not affected by performance status in patients with metastatic colorectal cancer: A meta-analysis | Giuseppe Colloca | ![]() |
![]() |
|||
P-206 | Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience | Rita Gameiro-dos-Santos | ![]() |
![]() |
|||
P-207 | FLOT in clinical practice: Retrospective analysis of an oncological center | Raquel Fontes | ![]() |
![]() |
|||
P-208 | Pancreatic neuroendocrine neoplasia: Experience of a comprehensive cancer center | Sara Coelho | ![]() |
![]() |
|||
P-209 | Cancers of the bile duct: A study of 30 cases | benamar wassila | ![]() |
![]() |
|||
P-210 | Capecitabine and temozolomide for metastatic neuroendocrine neoplasms: A single-center real-word data analysis | Ana Caetano | ![]() |
![]() |
|||
P-211 | Risk of diabetes in subjects with positive fecal immunochemical test: A nationwide population-based study | Hyun Jung Lee | ![]() |
![]() |
|||
P-212 | The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma | Ruijingfang Jiang | ![]() |
![]() |
|||
P-213 | Helicobacter pylori babA gene evolution and adaptation in Colombian populations | Kevin Guzman | ![]() |
![]() |
|||
P-214 | Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study | Nikolaos Tsoukalas | ![]() |
![]() |
|||
P-215 | Short-term results and survival outcomes following resection of localized pancreatic neuroendocrine tumors: a brazilian single center experience. | Dante Arra | ![]() |
![]() |
|||
P-216 | Gender-specific genomic alterations among Hispanic patients with metastatic colorectal cancer | Sayed Reshad Ghafouri | ![]() |
![]() |
|||
P-217 | The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study | HUIFANG XU | ![]() |
![]() |
|||
P-218 | STAT3 signaling inhibition in regulatory T cells improves immune response to RT in PDAC | Miles Piper | ![]() |
![]() |
|||
P-219 | Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study | Cagatay Arslan | ![]() |
![]() |
|||
P-221 | Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase I/II trial | Line Tarpgaard | ![]() |
![]() |
|||
P-222 | Dihydropyrimidine dehydrogenase deficiencies and fluoropyrimidine toxicities: A study in the Tunisian Center | Melliti Rihab | ![]() |
![]() |
|||
P-223 | Gasdermin B predicts good prognosis and more macrophage infiltration | liang Sun | ![]() |
![]() |
|||
P-224 | Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study | Anastasia Kottorou | ![]() |
![]() |
|||
P-225 | Clinico-epidemiological and therapeutic profile of rectal cancer: Experience of the department of radiation oncology EHSO ORAN | meriem cheriguene | ![]() |
![]() |
|||
P-226 | Trifluridin/tipiracil and regorafenib sequencing in Slovenian patients with metastatic colorectal cancer | Tanja Mesti | ![]() |
![]() |
|||
P-227 | Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis | Zhaolun Cai | ![]() |
![]() |
|||
P-228 | Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease | Anna Virgili | ![]() |
![]() |
|||
P-229 | Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma | Julien Edeline | ![]() |
![]() |
|||
P-230 | Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic? | Thiery Chapelle | ![]() |
![]() |
|||
P-231 | Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis | Hannah Christina Puhr | ![]() |
![]() |
|||
P-232 | Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients | Sally Temraz | ![]() |
![]() |
|||
P-233 | Patient information and management by eHealth intervention during colon cancer | Melina Campagnaro | ![]() |
![]() |
|||
P-234 | Participation of screening and barriers in Chinese patients with advanced colorectal cancer before diagnosis: A national multi-center cross-sectional study | Yin Liu | ![]() |
![]() |
|||
P-235 | E-health monitoring during pancreatic cancer treatment | Melina Campagnaro | ![]() |
![]() |
|||
P-237 | Clinical doctors attitudes towards colorectal cancer genetic testing: A national multi-center cross-sectional study | Yin Liu | ![]() |
![]() |
|||
P-238 | Clinicopathological profile and prognostic factors impacting survival of periampullary carcinoma: A tertiary care centre experience | ADITYA KUMAR SINGLA | ![]() |
![]() |
|||
P-239 | Consensus molecular subtypes of morphological regions on colorectal tumors | Vlad Popovici | ![]() |
![]() |
|||
P-240 | The diagnosis and treatment of advanced colorectal cancer in China: A national multi-center cross-sectional study | HUIFANG XU | ![]() |
![]() |
|||
P-243 | A prospective study to assess the impact of colostomy on psychosocial aspects of quality of life in colorectal cancer patients | Divya Khosla | ![]() |
![]() |
|||
P-244 | Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent | Lalchhandami Colney | ![]() |
![]() |
|||
P-245 | Evaluation of colon-specific plasma nanovesicles as new markers of colorectal cancer | Inga Nazarova | ![]() |
![]() |
|||
P-250 | Epidemiological, diagnostic and therapeutic profile of pancreatic cancer: Experience of a medical oncology department | Somia Chaibdra Tani | ![]() |
![]() |
|||
P-252 | Residual fibrosis after treatment with anti-epidermal growth factor receptor or bevacizumab in colorectal liver metastases and its correlation with survival: A retrospective pooled analysis | Xavier Hernández-Yage | ![]() |
![]() |
|||
P-253 | Detection of potential molecules that might be implicated in colorectal metastasis to lung | Panagiotis Apostolou | ![]() |
![]() |
|||
P-255 | The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy - preliminary results | Pawe&322; Stelmasiak | ![]() |
![]() |
|||
P-256 | Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition | Chiara Bazzichetto | ![]() |
![]() |
|||
P-258 | Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer | Size Chen | ![]() |
![]() |
|||
P-261 | Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma | Sarina Piha-Paul | ![]() |
![]() |
|||
P-262 | Highly sensitive quantification of Extracellular Vesicles Derived From Colorectal Cancer | Nadezhda Nikiforova | ![]() |
![]() |
|||
P-263 | The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma | Yiguang Lin | ![]() |
![]() |
|||
P-264 | Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia | Kevin Guzman | ![]() |
![]() |
|||
P-265 | Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guys cancer cohort experience | Kasia Owczarczyk | ![]() |
![]() |
|||
P-266 | Oncological outcomes of self-expanding metal stents as a bridge to surgery for obstructive left-sided colon cancer | Laura Gomez Fernandez | ![]() |
![]() |
|||
P-267 | Interleukin-8 levels as a predictor of colorectal cancer patient prognosis | Fabiana Conciatori | ![]() |
![]() |
|||
P-268 | Seaweed laminaria japonica peptides possess strong anti-liver cancer effects | Hongjie Chen | ![]() |
![]() |
|||
P-269 | Advanced gastric cancer bleeding: Association of hemostatic radiotherapy and iron supplementation - Is there a survival benefit? | André Laranja | ![]() |
![]() |
|||
P-270 | Impact of intestinal stoma on quality of life in Tunisian patients with colorectal cancer | NOUHA AMMAR | ![]() |
![]() |
|||
P-271 | The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells | Hongjie Chen | ![]() |
![]() |
|||
P-272 | Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer | Yusuke Nagata | ![]() |
![]() |
|||
P-273 | Mucinous colorectal cancer in Tunisian patients: A controversial clinicopathological type | Haifa TOUNSI GUETTITI | ![]() |
![]() |
|||
P-274 | Exploratory analysis of potential clinical, molecular and analytical prognostic factors of real-world patients with gastrointestinal stromal tumors: A single center study | Ignacio Perez Criado | ![]() |
![]() |
|||
P-275 | Evaluation of radical chemoradiation outcomes in stage II/III anal cancer: Real-world data population | Isabel Fernandes | ![]() |
![]() |
|||
P-278 | Checkpoint Inhibitors in Patients with Advanced, Refractory Biliary Tract Cancers | Savannah Liddell | ![]() |
![]() |
|||
P-279 | Thromboembolic complications in colorectal cancers | nassima mkedder | ![]() |
![]() |
|||
P-280 | HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma | Robert Merker | ![]() |
![]() |
|||
P-281 | Low proliferation indexes in colorectal cancer in Tunisian patients: Association with rectal localization, mucinous histological type and stage | Dorra Wider | ![]() |
![]() |
|||
P-282 | Factors predicting response to neoadjuvant chemotherapy in gastric cancer | Pavan Kumar C G | ![]() |
![]() |
|||
P-283 | Prognostic factors in the evaluation of stage II/III squamous cell carcinoma of the anus treated with chemoradiation | João Gramaa | ![]() |
![]() |
|||
P-284 | Exploratory magnetic resonance imaging histogram biomarkers for response prediction to neoadjuvant treatment in oesophageal/gastro-oesophageal cancer | Kasia Owczarczyk | ![]() |
![]() |
|||
P-285 | Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study | Juraj Prejac | ![]() |
![]() |
|||
P-286 | Assessment of the quality of life of patients with colorectal cancer in the Tunisian Center: A report of 142 patients | Imtinene Belaid | ![]() |
![]() |
|||
P-287 | Preclinical evaluation of alpelisib (PI3K inhibitor ) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer | razia aslam | ![]() |
![]() |
|||
P-288 | Individual drug-screening and heterogeneity analyses of patient-derived tumoroids: A roadmap to improving therapy in pancreatic cancer | Christine Nitschke | ![]() |
![]() |
|||
P-289 | Gastric and esophageal signet ring cell adenocarcinoma: A retrospective analysis of outcomes at Mayo Clinic | Zhubene Mesbah | ![]() |
![]() |
|||
P-290 | Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer | Nirit Yarom | ![]() |
![]() |
|||
P-291 | The prognostic and predictive factors for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy | Banu Ozturk | ![]() |
![]() |
|||
P-292 | Tumor downstaging as an associated factor with recurrence of disease in patients with operated rectal cancer after neoadjuvant chemoradiotherapy: Real-world data from Peru | Rodrigo Motta | ![]() |
![]() |
|||
P-294 | Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: A systematic review and meta-analysis | Zhiyuan Jiang | ![]() |
![]() |
|||
P-295 | The importance of sphingosine kinase 1 isoform expression in the gut-liver axis | Hongjie Chen | ![]() |
![]() |
|||
P-296 | Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer | Shuzhi Ma | ![]() |
![]() |
|||
P-297 | Upfront dihydropyrimidine dehydrogenase deficiency detection to secure 5-FU or capecitabine administration: Application to colorectal cancer patients | nassima mkedder | ![]() |
![]() |
|||
LBA-298 | Response to Total Neoadjuvant Therapy and Survival in Patients with Early Onset Locally Advanced Rectal Cancer | Melissa Lumish | ![]() |
![]() |
30 June - 3 July 2021 Virtual Conference
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|